Please login to the form below

Not currently logged in
Email:
Password:

Positive opinion for Zevalin

Bayer Schering Pharma AG announced on March 20 that the European Committee for Medicinal Products for Human Use gave a positive opinion for its drug Zevalin
Bayer Schering Pharma AG announced on March 20 that the European Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for its drug Zevalin.

Pending a favourable review from the European Commission, Zevalin could receive marketing authorisation for all EU member states later this year.

Zevalin (ibritumomab tiuxetan) has been developed as a consolidation therapy for patients with follicular lymphoma, one of the most common types of non-Hodgkin's lymphoma, the fifth most prevalent form of cancer.

Dr Gunnar Riemann, member of the board of management for Bayer, said: "The CHMP's recommendation represents an important milestone for Zevalin."

"This therapy option will provide clinicians with a treatment regimen that truly could help many of their patients to an extended progression-free survival," he added.

25th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics